DOCSLIB.ORG

Real Or Perceived Amyotrophic Lateral Sclerosis (ALS) Objectives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Real Or Perceived Amyotrophic Lateral Sclerosis (ALS) Objectives 10/11/2019 Nursing Care and Considerations of Patients with Amyotrophic Lateral Sclerosis (ALS) 40th Annual Neurorehabilitation Conference on Traumatic Brain Injury, Stroke and Other Neurological Disorders Saturday & Sunday, November 16 & 17, 2019 Hyatt Regency Cambridge 575 Memorial Drive • Cambridge, MA encompasshealth.com/braintreerehab Vincent M. Vacca, Jr., MSN, RN 1 Conflicts of interest – Real or Perceived • NONE 2 Amyotrophic Lateral Sclerosis (ALS) Objectives: 1. Following this presentation the learner will be able to list three signs and symptoms of motor neuron dysfunction found in ALS. 2. Following this presentation the learner will be able to explain three diagnostic tests utilized to establish diagnosis of ALS. 3. Following this presentation the learner will be able to describe three essential nursing interventions guided by best practices and care of patients with ALS. 3 1 10/11/2019 The median age of ALS onset is 55 years • ALS affects about one in every 300 people. • About 30,000 currently with 5,000 new cases per year. • ALS is sporadic in 90% of cases and show familial inheritance in the remaining 10%. • Estimates of the median survival of people with ALS vary between 27 and 64 months. • Death from ALS is primarily pulmonary. 4 ALS is the most frequent motor neuron disorder in adults • Due to degeneration of upper and lower motor neurons in spinal and bulbar myotomes. • Most studies show male predominance with a gender ratio of 3:2, but gender differences are age related. • Age of onset tends to be later in females than in males (68.4 years vs. 61.5 years). • Limb-onset ALS is more frequent in males and bulbar onset predominates in females in all age groups. 5 There are multifactorial pathogenic processes underlying ALS • which are not yet fully determined. • Cellular events: • Oxidative stress, • Mitochondrial dysfunction, • Excitotoxicity (Glutamate), • Protein aggregation, • Impaired axonal transport, • Neuroinflammation, and • Dysregulated RNA signaling, • All can contribute to ALS. 6 2 10/11/2019 Upper & Lower Motor Neurons • Clinical findings indicate where damage occurs: UMN v. LMN. • UMN disease/lesion/disorder results in increased muscle tone/reflexes. • Signs of UMN lesion: Weakness/Spasticity/Hyper-reflexia/ + Babinski/Clasp Knife. • LMN lesion results in decreased/absent muscle tone/reflexes. • Signs of LMN lesion: Weakness/Spasticity/Reduced tone & reflexes/fasiculations. 7 8 ALS – Lou Gehrig’s Disease •Disease is motor not sensory. •May not see all the UMN & LMN signs but should see a mix of both. 9 3 10/11/2019 ALS is now universally recognized as a complex multisystem disorder • Approximately 15% of ALS patients have overt frontotemporal dementia (FTD), • and an additional 30–40% may have less severe cognitive impairment, that manifests largely as frontal lobe executive dysfunction. 10 Convincing evidence supports that ALS is a multisystem disease •not limited to motor areas alone but involving extra-motor areas as well and causing a variable degree of: •Cognitive, •Behavioral, •Dys-autonomic symptoms. 11 ALS symptoms usually begin in the distal limb or bulbar musculature, • and typically spread, causing progressive muscle weakness and eventually leading to death by respiratory insufficiency. • The median survival from symptom onset is 2–3 years, but there are great individual variations: (1) body region of onset (bulbar vs. spinal); (2) relative mix of UMN and LMN involvement; (3) progression rate; (4) age of onset, and (5) the presence of extra-motor symptoms. 12 4 10/11/2019 ALS • Will see ‘generalized’ weakness particularly - limb muscles. • The extra-ocular muscles/movements (EOMs) are preserved. • Many other cranial nerves affected leading to a ‘nasal speech’ pattern/swallowing impairment. (Bulbar) 13 Myelin sheath of nerves: • Oligodendrocytes produce myelin. • Myelin facilitates signal transmission through the nerves at a rapid rate so we can respond to our environment in a split second. • In ALS oligodendrocytes degenerate and myelin is abnormal. 14 S&S – Bulbar & Limbs • Voluntary muscle weakness, stiffness, twitching, cramps, spasticity, difficulty with posture, muscle atrophy, stiffness, slurred/nasal speech, dysphagia, chewing. • Usual onset is in arms/hands – will have difficulty writing or buttoning a shirt/tying a shoe for example. • If legs – awkward gait, stumbling, tripping. • Later stages: dyspnea & dysphagia. • Difficulties with Speaking/Swallowing & Breathing – eventual respiratory failure. • Poor prognosis and decreased survival time correlate with the nutritional status of patients with ALS. • If speech related symptoms appear first it’s called Bulbar onset ALS. • If limbs first – it’s Limb onset ALS. 15 5 10/11/2019 Weight loss and malnutrition are two common features of ALS • associated with a poor prognosis. • There is evidence suggesting that increased energy intake and a higher body mass index (BMI) of 30–35 may slow ALS progression and alter the clinical course of the disease. • Alter food consistency, integrate postural advice such as tucking the chin and flexing the neck when eating, consume oral nutrition supplements, and enteral or parenteral nutrition. • The value of EN likely exceeds that of maintaining BMI, studies have shown that EN can significantly decrease anxiety related to choking and, improve quality of life. 16 Review: Executive dysfunction is the most commonly cited cognitive impairment in ALS • Executive function encompasses several higher-order processes: • planning, • organization, • goal-directed activity, • working memory, • initiation, • behavioral regulation, and inhibitory control, • situation-appropriate decision-making on the basis of projected positive and negative outcomes in novel, complex or ambiguous situations. • Verbal fluency impairment has been consistently reported in ALS. • Language dysfunction is increasingly recognized as a core feature of ALS and has been consistently detected in patients without executive dysfunction. 17 Adherence to treatment - cognitive dysfunction; • compliance with assistive devices, • participation in clinical trials, • making informed financial and end-of-life decisions, • choices in participating in non-licensed treatments are just some of the aspects of a patient journey which may be significantly affected by cognitive or behavioral deficits. • Cognitive impairment in ALS is widely regarded as a negative prognostic indicator and linked to reduced survival. • Neuropsychological deficits in ALS are thought to be associated with increased caregiver burden and reduced quality of life. • The recognition of the far-reaching effects of neuropsychological deficits on nearly all aspects of ALS care, caregiver support, resource allocation, and prognosis, led to the inclusion of specialist neuropsychologists as core members of ALS multidisciplinary teams worldwide. 18 6 10/11/2019 ALS survival • ~50% live up to 3 years after diagnosis. • ~10% live > 10 years after diagnosis. • Can affect anyone regardless of race/gender/ethnicity. • Does not affect senses of touch, smell, hearing, vision and taste. • No apparent risk factors – 90-95% occurs randomly. • 5-10% genetic. • Death is usually caused by respiratory failure - loss of motor neurons supplying innervation to the diaphragm and chest wall muscles. • The rate of decline of Forced Vital Capacity (FVC) predicts survival of patients with ALS. 19 ALS diagnosis • Helpful to also ask a family member about some of the changes as the patient may not notice it as keenly as another. • Ex. Have your muscles shrunk or your voice changed. • Early diagnosis is challenging as the signs may be minimal. • The changes with ALS are consistent and progressive. • There are not ‘good’ days or ‘bad’ days. 20 ALS is a deadly disease – accurate diagnosis essential. • Electromyogram (EMG) is an accurate & confirmatory test for ALS done while patient is alive. • Patients/families need to understand the diagnosis. • End-of-life planning becomes essential. 21 7 10/11/2019 Early diagnosis offers the best prognosis for a longer, quality life while living with the disease. • Many medications are used to relieve symptoms but there are only 2 pharmacologic agents indicated for the management of ALS. • For 2 decades, riluzole had been the mainstay of disease-modifying therapy, but in 2017, edaravone became the second agent approved in the management of patients with ALS. • The mechanism of either agent is not well known. • Riluzole is thought to reduce damage to motor neurons through an inhibitory effect on glutamate release. • Edaravone is thought to act as a neuroprotective agent that prevents oxidative stress damage as a free radical scavenger. 22 • Muscle biopsy to investigate muscles in more detail. ALS Diagnosis • Electromyography (EMG) to measure electrical activity of muscles during contraction and relaxation. • No Specific test – like a biomarker. • Cortical thickness seems to be the • MRI – Can rule out herniated disc most promising neuroimaging (cervical), spinal cord tumors etc…w/ biomarker of ALS. similar symptoms. • Quantitative iron imaging is a very • Nerve conduction studies (NCS) – promising biomarker in ALS. measure ability of nerves to send impulses to muscles. • Diagnostic testing is done to exclude other neurologic • Genetic testing. conditions that have some • Electrical impedance myography - can similarity to ALS. measure changes in affected muscles – can also be used predict spread to other muscles. 23 Potential ALS mimickers include • cerebral lesions, • skull
Load more

Recommended publications
  • 46 L Nursing2015 L Volume 45, Number 10 46 L
    46 l Nursing2015 l Volume 45, Number 10 www.Nursing2015.com Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. 2.0 ANCC ALCONTACT HOURSS Amyotrophic lateral sclerosis: What nurses need to know By Tamara L. Bellomo, MSN, RN-BC, and Lucille Cichminski, MSN, RN A MOTHER OF THREE teenage children, Mrs. is one of the most common neuromuscular dis- S, 49, presented to her healthcare provider eases in the world. This rapidly progressive, fatal with bilateral leg twitching and weakness, dif- neuromuscular disease involves the degeneration ficulty swallowing, and fatigue that’s worsened and death of the upper and lower motor neu- over the past few weeks. While she was on her rons.1 This article discusses the diagnosis and daily morning walk, she tripped and fell. She treatment of ALS and how nurses can help their experienced a small laceration to her leg, patients deal with the difficult diagnosis and find prompting her visit to the healthcare facility. the resources they and their families need. Her husband said that she’d had periods of slurred speech over the past few months as Who’s affected? well. She was alert and oriented, and her vital An estimated 20,000 to 30,000 Americans are signs were all within normal limits. living with ALS, and about 5,000 new cases After an exam, her healthcare provider are diagnosed each year in the United States.2 referred her to a neurologist who ordered This disease affects people of all ethnic, socio- magnetic resonance imaging (MRI), an electro- economic, and racial backgrounds.2,3 ALS most HOTOTAKE / P myogram, and a full bloodwork panel.
    [Show full text]
  • FUNDELA Boletín Científico 45
    ABRIL 2013 Fundación Española para el Fomento de la Investigación de la Esclerosis Lateral Amiotrófica FUNDELA Boletín Científico 45 El boletín de FUNDELA publica resúmenes y artículos científicos referentes a los últimos avances de la investigación, tratamientos sintomáticos y cuidados al paciente con ELA. Se envía periódicamente a más de 400 suscriptores, entre los que se encuentran profesionales de la salud, pacientes y familiares de España y Latinoamérica. Todos los boletines pueden descargarse en nuestra web www.fundela.es FUNDELA no asume responsabilidades por la información que contiene este boletín. Necesitamos ayuda económica para continuar en los proyectos que indicamos a continuación •PROYECTOS PILOTO DE DETERMINACION DE DIFERENTES POSIBLES BIOMARCADORES EN PLASMA Y CELULAS MONONUCLEARES DE SANGRE PERIFERICA EN PACIENTES CON ELA •PUESTA A PUNTO DE UN ALGORITMO MOLECULAR DIAGNOSTICO EN PACIENTES CON ELA Y DEGENERACION LOBULAR FRONTOTEMPORAL •REHABILITACIÓN EN ESCLEROSIS LATERAL AMIOTRÓFICA: TERAPIA OCUPACIONAL Y LOGOPEDIA •BOLETIN CIENTIFICO Actualmente contamos con subvenciones de SEALED AIR BUÑOL, Fundación MUPITI y FRANHUR, La Caixa y aportaciones particulares de pacientes y familiares que sufren la ELA. Su donativo le dará derecho a practicar una deducción en la cuota del impuesto sobre la renta. La deducción será del 25% como persona física y del 35% como empresa. Para realizar donaciones económicas pedimos suscribirse en nuestra página web: http://www.fundela.es/captaBanco.php Colaboradores voluntarios de este número: Dr. Alberto García Redondo (Bioquímico, Unidad Hospital 12 de octubre) de ELA – Hospital 12 de octubre) Dra. María Teresa Solas (Bióloga, Universidad Dra. Elena Rodríguez García (Bioquímica – Complutense) Voluntaria FUNDELA) Dra. Teresa Salas (Psicóloga, Unidad de ELA - Dr.
    [Show full text]
  • BOOK of ABSTRACTS OXFORD ENCALS Meeting 2018
    2018 MEETING 20-22 JUNE 2018 BOOK OF ABSTRACTS OXFORD ENCALS Meeting 2018 Acknowledgements ENCALS would like to thank the following sponsors for their generous support of this year’s meeting. Gold Sponsor Silver Sponsors Bronze Sponsors 2 ENCALS Meeting 2018 Poster Session 1: Wednesday 20th June, 18:00 - 19:30 Entrance Hall: A01 Hot-spot KIF5A mutations cause familial ALS David Brenner* (1), Rüstem Yilmaz (1), Kathrin Müller (1), Torsten Grehl (2), Susanne Petri (3), Thomas Meyer (4), Julian Grosskreutz (5), Patrick Weydt (1, 6), Wolfgang Ruf (1), Christoph Neuwirth (7), Markus Weber (7), Susana Pinto (8, 9), Kristl G. Claeys (10, 11, 12), Berthold Schrank (13), Berit Jordan (14), Antje Knehr (1), Kornelia Günther (1), Annemarie Hübers (1), Daniel Zeller (15), The German ALS network MND-NET, Christian Kubisch (16, 17), Sibylle Jablonka (18), Michael Sendtner (18), Thomas Klopstock (19), Mamede de Carvalho (8, 20), Anne Sperfeld (14), Guntram Borck (16), Alexander E. Volk (16, 17), Johannes Dorst (1), Joachim Weis (10), Markus Otto (1), Joachim Schuster (1), Kelly del Tredici (1), Heiko Braak (1), Karin M. Danzer (1), Axel Freischmidt (1), Thomas Meitinger (21), Tim M. Strom (21), Albert C. Ludolph (1), Peter M. Andersen (1, 9), and Jochen H. Weishaupt (1) Heterozygous missense mutations in the N-terminal motor or coiled-coil domains of the kinesin family member 5A (KIF5A) gene cause monogenic spastic paraplegia (HSP10) and Charcot-Marie-Tooth disease type 2 (CMT2). Moreover, heterozygous de novo frame-shift mutations in the C-terminal domain of KIF5A are associated with neonatal intractable myoclonus, a neurodevelopmental syndrome.
    [Show full text]
  • Drug Development for Amyotrophic Lateral Sclerosis Guidance for Industry
    Drug Development for Amyotrophic Lateral Sclerosis Guidance for Industry August 2017 Contents I. INTRODUCTION ................................................................................................................ 1 II. BACKGROUND ................................................................................................................... 2 III. BENEFIT RISK...................................................................................................................... 5 A. General comments .................................................................................................................. 5 B. Evidence of patient and caregiver preferences ....................................................................... 5 C. Implications of patient risk/benefit preferences in ALS ......................................................... 7 1. Alternative endpoints........................................................................................................... 7 2. Placebo control arm ............................................................................................................. 8 3. Threshold for statistical significance ................................................................................... 9 4. Method of delivery ............................................................................................................ 10 5. Role of expanded access and accelerated approval ........................................................... 11 6. Patient protection and need for informed
    [Show full text]
  • 2020-ALS-Mission-Toolkit Web.Pdf
    OUR MISSION OUR MISSION TABLE OF CONTENTS OUR MISSION Our Case for Support . iv Annual Impact . v Our Vision and Mission . vi CHAPTER 1: RESEARCH The ALS Association Research Program The ALS Association Research Program . 1–1 Research . 1–5 Our Strategic Initiatives . 1–5 Infographics Current Projects . 1–13 Accelerating the Search for a Cure . 1–14 Research By the Numbers . 1–15 Research Strategy . 1–16 Funded Research . 1–17 Scientific Focus Areas . 1–18 Advances in ALS Research . 1–20 Research Initiatives The ALS Association’s ALS Roundtable Program . 1–22 ALS Voice of The Patient Report . 1–24 ALS Focus Survey Program . 1–26 Research Staff . 1–28 CHAPTER 2: CARE SERVICES How We Work Summary . 2–1 How We Work . 2–2 Chapter Membership . 2–4 ii How We Support Clinical Care Supporting Clinical Care . 2–11 Certified Centers . 2–14 Where We Support Care . 2–15 Impact & Resources Care Services Impact . 2–20 Filling the Gap . 2–21 Education — Living with ALS: General Scope . 2–22 Education — Living with ALS: Medical Resources . 2–24 Assistive Technology — Assistive Technology in the ALS Space . 2–26 Children’s Programs and Resources . 2–28 The Jane Calmes ALS Scholarship Fund . 2–32 ALS Association Care Connection . 2–33 Care Services Staff . 2–34 CHAPTER 3: ADVOCACY Introduction To ALS Advocacy Introduction . 3–1 History of ALS Advocacy . 3–2 History of ALS Advocacy: Timeline . 3–3 Advocacy Action Advocacy Guiding Principles . 3–5 How We Advocate . 3–6 Priorities, Impact, and Coalitions ALS Guidance . 3–10 Advocacy Impact .
    [Show full text]
  • A Er the Wildly Successful Ice Bucket Challenge
    RESEARCH FEBRUARY/MARCH 2015 BY GINA SHAW Azer the Wildly Successful Ice Bucket Challenge ~e Ice Bucket Challenge raised big bucks on social media. Now, the ALS Association tells us where that cold, hard cash is going. As snowstorms and icy winds batter much of the country, it's hard to imagine willingly pouring a bucket of ice water over your head for any reason. But last August—when temperatures were much more forgiving—that's exactly what about 3 million people did. In an astonishing example of the power of social media, a July 31 dare from former Boston College baseball player Pete Frates, who was diagnosed with amyotrophic lateral sclerosis (ALS) in 2012, quickly went viral. The dare? Dump ice water on your head within 24 hours of being challenged or donate $100 (or whatever amount you could afford) to the ALS Association or another organization supporting ALS research. Pretty soon, the Ice Bucket Challenge meant dumping ice on your head and donating money, and everyone from your neighbor's preschooler to Bill Gates (with a custom-built ice douser), Oprah Winfrey, Jon Bon Jovi, and entire casts of Broadway shows were doing it—and posting their videos online. Even 86-year-old Ethel Kennedy took the challenge. (President Obama donated but declined the ice; actor Patrick Stewart posted a video of himself writing a check.) In La Jolla, CA, prominent ALS researcher Don Cleveland, PhD, who pioneered a novel therapy that turns off the defective genes that contribute to neurodegenerative diseases, watched the online commotion with skepticism.
    [Show full text]
  • Technologies for Improving the Lives of People With
    Technologies for improving the UW CSE MSR Summer lives of people with ALS Institute 2016 Rico Malvar Expanding Chief Scientist and Distinguished Engineer Accessibility Research What is ALS (Lou Gehrig’s Disease) • ALS, or amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. A-myo-trophic comes from the Greek language. "A" means no. "Myo" refers to muscle, and "Trophic" means nourishment – "No muscle nourishment." When a muscle has no nourishment, it "atrophies" or wastes away. Lateral identifies the areas in a person's spinal cord where portions of the nerve cells that signal and control the muscles are located. As this area degenerates it leads to scarring or hardening ("sclerosis") in the region. • Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their demise. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, people may lose the ability to speak, eat, move and breathe. The motor nerves that are affected when you have ALS are the motor neurons that provide voluntary movements and muscle control. Examples of voluntary movements are making the effort to reach for a smart phone or step off a curb. These actions are controlled by the muscles in the arms and legs. Source: “What is ALS”, ALS Association Ten Things about ALS 1. Every 90 minutes someone in the US is diagnosed with ALS.
    [Show full text]
  • 24Th Annual Meeting Sunday and Monday, 4-‐5 December 2016
    24th Annual Meeting Sunday and Monday, 4-5 December 2016 Liffey Hall 2, Convention Centre Dublin AGENDA SUNDAY, 4 DECEMBER 2016 08:45 1 Welcome & Introduction (30 min) 09:15 Annual General Meeting (45 min) 10:00 2 Opening Remarks from the General Manager (15 min) 10:15 Morning Refreshments (30 min) 10:45 3 Welcoming Our NeW Members (15 min) 11:00 Programming for PALS/CALS (60 min) 4 Beyond Awareness Gaps Hiroki Okabe, Japan ALS Association 5 The Cost of Achieving Your Goals: Assistive Technology Program in Israel Efrat Carmi, IsrALS 6 A Comprehensive Information and Education Resource for People with MND, their Carers, Health and Community Care Providers Gina Svolos, MND Australia 7 New Challenges to Our Association Alessandra Dorca, ALS Pro-Cura Association 12:00 Lunch (60 min) 13:00 Programming for PALS/CALS Continued (30 min) 8 ACELA: A Vision of Hope Rocio Reyes, ACELA, Colombia 9 Life Is Now Gudjon Sigurdsson, MND Iceland 13:30 Partnerships and Collaborations (90 min) 10 A Phased Shift in MND Care in Scotland Craig Stockton, MND Scotland 11 Victories and Partnerships Tatiana Mesquita e Silva, ABrELA 12 Local Fundraising for Project MinE Gorrit-Jan Blonk, ALS Netherlands 13 Using the MND Association’s Experience to Promote Optimal Care and Support in Russia Anna Kassianova, Martha-Mary Medical Centre “Miloserdie” 14 The South African MND Caregiving Experience: Lessons Learned from a Cross-Country Collaboration Melinda Kavanaugh, University of Wisconsin-MilWaukee 15 First Ever ALS Student Exchange Jodi O’Donnell, Hope Loves Company
    [Show full text]
  • How Common Are ALS Plateaus and Reversals?
    How common are ALS plateaus and reversals? Richard S. Bedlack, MD, ABSTRACT PhD Objective: To determine the frequency of amyotrophic lateral sclerosis (ALS) plateaus and rever- Timothy Vaughan, PhD sals in the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database. Paul Wicks, PhD Methods: We analyzed Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) and Jamie Heywood ALSFRS–revised (ALSFRS-R) data from PRO-ACT participants. The frequencies of participants Ervin Sinani experiencing plateaus (periods where scores did not change) were calculated over 6-, 12-, and Roger Selsov 18-month epochs. The percentage of participants ever experiencing reversals (periods where Eric A. Macklin, PhD scores improved) of different lengths were also calculated and plotted. David Schoenfeld, PhD Merit Cudkowicz, MD Results: Over 6 months, 25% of 3,132 participants did not decline. Over 12 months, 16% of Alex Sherman 2,105 participants did not decline. Over 18 months, 7% of 1,218 participants did not decline. Small ALS reversals were also common, especially over shorter follow-up intervals; 14% of 1,343 participants had a 180-day interval where their ALSFRS-R slope was greater than zero. Correspondence to Fewer than 1% of participants ever experienced improvements of 4 or more ALSFRS-R points Dr. Bedlack: lasting at least 12 months. [email protected] Conclusion: ALS plateaus and small reversals are common, especially over brief intervals. In light of these data, stable disease, especially for a short period of time, should not be interpreted as an ALS treatment effect. Large sustained ALS reversals, on the other hand, are rare, potentially important, and warrant further study.
    [Show full text]
  • Amyotrophic Lateral Sclerosis (ALS)?
    Amyotrophic Lateral Sclerosis U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Amyotrophic Lateral Sclerosis What is amyotrophic lateral sclerosis (ALS)? myotrophic lateral sclerosis (ALS) is a A rare neurological disease that affects nerve cells (neurons) in the brain and spinal cord that control voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, breathing and talking. The disease is progressive, meaning the symptoms get worse over time. Currently, there is no cure for ALS and no effective treatment to halt, or reverse, the progression of the disease. ALS belongs to a wider group of disorders known as motor neuron diseases, which are caused by gradual deterioration (degeneration) and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body. These motor neurons initiate and provide vital communication links between the brain and the voluntary muscles. Messages from motor neurons in the brain (called upper motor neurons) are transmitted to motor neurons in the spinal cord and to motor nuclei of brain (called lower motor neurons) and from the spinal cord and motor nuclei of brain to a particular muscle or muscles. 1 In ALS, both the upper motor neurons and the lower motor neurons degenerate or die, and stop sending messages to the muscles. Unable to function, the muscles gradually weaken, start to twitch (called fasciculations), and waste away (atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. Early symptoms of ALS usually include muscle weakness or stiffness. Gradually all muscles under voluntary control are affected, and individuals lose their strength and the ability to speak, eat, move, and even breathe.
    [Show full text]
  • Guidance for Industry Drug Development for Amyotrophic Lateral Sclerosis
    Guidance for Industry Drug Development for Amyotrophic Lateral Sclerosis ALS Guidance Participants The following individuals were leading participants in the patient-centered, community-led ALS Guidance initiative. Steering Committee: • Barb Newhouse, Steering Committee Chair; President and CEO, The ALS Association • Lucie Bruijn, Steering Committee Vice Chair; Chief Scientist, The ALS Association • Hiroshi Mitsumoto, Steering Committee Vice Chair; Columbia MDA/ALS Research Center • Rick Bedlack, chair, Public Policy working group; Duke University Medical Center • James Berry, chair, Biomarkers working group; Massachusetts General Hospital • Benjamin Brooks, chair, Benefit/Risk working group; Carolinas Health System • Merit Cudkowicz, co-chair, Clinical Trials and Outcome Measures working group; Massachusetts General Hospital • Valerie Cwik, Muscular Dystrophy Association, EVP and Chief Medical and Scientific Officer • Ted Harada, co-chair, Patient & Caregiver Advisory Committee; Person with ALS, ALS Association National Trustee • Don Johns, Steering Committee Member; Vice President, Head ALS Neuroscience Discovery & Development, Biogen • Catherine Lomen-Hoerth, chair, FTD/ALS working group; UCSF • Nicholas Maragakis, chair, Diagnosis working group; Johns Hopkins Hospital • Tim Miller, chair, Natural History working group; Washington University School of Medicine • Elizabeth Ottinger, Steering Committee Member; NIH/NCATS • Steve Perrin, Steering Committee Member; ALS Therapy Development Institute, Chief Scientific Officer • Jeremy Shefner,
    [Show full text]
  • Brand Overview
    CHANNEL MARKETING Meetings Focus provides the most varied, success-proven array of products in the marketplace. As you review your marketing goals and needs for the coming year, look to each of the opportunities within Meetings Focus, and we can deliver the right solution-based package for you! Web Units Programs Online Digital & Listings Video & Display Mobile WEB Edition Rich Media Packages Remarketing PRINT National Demographic International Guide Trends Supplements Meetings National Demographic Custom E-List in a EMAIL Newsletters Newsletters Newsletters Rental Minute On Location Meetings Educational Custom Custom Video LIVE Focus Live! Webinars Webinars FAM Broadcasts Lead Custom MARKETING Research SERVICES Generation Content NOVEMBER 2014 | MEETINGSFOCUS.COM The ALS Ice Bucket others, a great way to raise support.” videos, share an experience with others, and Challenge–a Brilliant Entry into the movement didn’t even have to feel like they were participating in a good, to cost money. Those who didn’t donate did charitable cause that was authentic. Many advocacy campaign! their bit to move a message and motivate would not have taken the dive into cold THE DESTINATION EXPERTS others. The playing field was level and many water had it not been for the charity piece. By Roger Rickard got onto it. “Emotion moves people to do and think CVB UPDATE things,” Rickard says. “I tell people to watch Editor’s note: The following excerpt was Harness Video Power. Videos are most the 70th anniversary video for the Ad sourced from a recent e-newsletter from likely to go viral these days on platforms Council on YouTube, and I ask them what Voices in Advocacy, a meetings industry A Special Advertising Section like Facebook and YouTube, as those about they see—emotion, children, pets, military, advocacy effort headed by Roger Rickard.
    [Show full text]